U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer

(Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Bristol-Myers Squibb Co's Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer.

Opdivo, part of a new class of medicines designed to use the body's own immune system to fight cancer, is already approved to treat advanced melanoma, a form of lung cancer, kidney cancer, and Hodgkin lymphoma.

Investors were disappointed last month when Bristol-Myers said it would not seek accelerated FDA approval for a combination of Opdivo and another immunotherapy, Yervoy, as an initial treatment for lung cancer.

The FDA is slated to decide in May whether to approve rival Merck & Co Inc's combination of immunotherapy Keytruda and chemotherapy for first-line lung cancer.

(Reporting By Deena Beasley; editing by Diane Craft)

Related News

Nestle unveils sushi-shaped KitKats in Japan

Feb 2, 2017

US-VALENTINES-DAY-NESTLE-SUSHI-KITKAT:Nestle unveils sushi-shaped KitKats in Japan

Madoff victims' recovery tops $9.7 billion with new payout

Feb 2, 2017

US-MADOFF-PAYOUT:Madoff victims' recovery tops $9.7 billion with new payout

School bullying linked to poorer academic achievement

Feb 2, 2017

US-HEALTH-BULLYING-SCHOOL-PERFORMANCE:School bullying linked to poorer academic achievement

You may also like these

Madoff victims' recovery tops $9.7 billion with new payout

Feb 2, 2017

US-MADOFF-PAYOUT:Madoff victims' recovery tops $9.7 billion with new payout

Parents of Canadian 'Sharkwater' filmmaker have hope for missing son

Feb 2, 2017

US-PEOPLE-STEWART:Parents of Canadian 'Sharkwater' filmmaker have hope for missing son

U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer

Feb 2, 2017

US-BRISTOL-OPDIVO-FDA:U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer

Search
Financial Markets

About Us

In the busy city of New York, News On Express fills you in with all the breaking world news, in short, and brief news articles so that you can read them on-the-go.

Contact us: sales@newsonexpress.com